We are SOPHiA GENETICS
SOPHiA GENETICS is the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine. Our global platform allows healthcare professionals to leverage their expertise and work together around the world – unlocking the promise of data-driven medicine at scale.
Our Brand
SOPHiA comes from the Greek Σοφία, meaning wisdom. Our brandmark is our guiding visual icon that symbolizes an eye processing different types of data in order to generate insights, which is the pink dot on the ‘i.’
Our Product
We offer a cloud-based Software-as-a-Service platform — the SOPHiA DDM™ platform — that enables healthcare institutions to get quick, robust insights from their data. We apply our technology to diseases such as cancer and inherited disorders, where combining genomic and phenotypic information is vital to support discoveries, treatment decisions, and drug development efforts.
Our People
We value diversity of background and mindset just as highly as experience and technical knowledge. Not only do more than 30% of our people hold PhDs in subjects as varied as cell biology and computer science, they’re also a potent mixture of ages, genders, backgrounds, and ethnicities spanning more than 28 countries.
SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology
Leading community-based practice to utilize increased set of solid tumor applications
SOPHiA GENETICS Launches MSK-IMPACT® powered with SOPHiA DDM™ at AMP 2024
Launch of new application enables global access to high-performing solid tumor profiling assay
SOPHiA GENETICS and Genomenon Collaborate to Streamline Genetic Research
BOSTON and ROLLE, Switzerland, November 6, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine,…
SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer
BOSTON, United States and ROLLE, Switzerland, November 5, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader…
SOPHiA GENETICS Reports Third Quarter 2024 Results
Clinical growth reaccelerates with record analysis volume; Cash burn improves 39% BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ — SOPHiA GENETICS (Nasdaq: SOPH),…
SOPHiA GENETICS to Announce Financial Results for Third Quarter 2024 on November 5, 2024
BOSTON and ROLLE, Switzerland, Oct. 22, 2024 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud- native software company and a leader…
SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most…
SOPHiA GENETICS Announces Poster Presentations at ESMO 2024
Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials.
SOPHiA GENETICS Announces Updates on SOPHiA UNITY at ESMO 2024
The global collective intelligence network aims to accelerate precision oncology research and care.
SOPHiA GENETICS and AstraZeneca Collaborate to Further Expand Global Access to Liquid Biopsy Testing
The companies commit to bring cutting-edge liquid biopsy testing to 20 institutions globally over the next 12 months